| Parameter* |
Nonresponders
to decitabine or treatment of choice† |
Responders to decitabine or treatment of choice†
(CR+CRi+PR) |
P value |
| Median overall survival, months |
4.3 |
17.4 |
<0.0001‡ |
| Intravenous antibiotic use (≥1 per patient) |
| Number of patients |
383 |
102 |
|
| Yes, n (%) |
38 (9.9) |
3 (2.9) |
0.024§ |
| Platelet transfusions (episodes per patient) |
| Number of patients |
373 |
102 |
|
| Mean (SD) |
3.03 (3.82) |
1.19 (2.35) |
P1<0.0001;
P2=0.796‖ |
| Median (range) |
1.8 (0–21) |
0.3 (0–14) |
|
| Number of transfusions/number of patient treatment cycles (proportion) |
3231 / 1492 (2.17) |
1025 / 1319 (0.78) |
|
| Red blood cell transfusions (episodes per patient) |
| Number of patients |
373 |
102 |
|
| Mean (SD) |
2.93 (2.54) |
1.42 (1.47) |
P1<0.0001
P2=0.872‖ |
| Median (range) |
2.3 (0–16) |
1.1 (0–10.5) |
|
| Number of transfusions/number of patient cycles (proportion) |
3642 / 1492 (2.44) |
1395 / 1319 (1.06) |
|
| Dose modifications based on dose reductions and delays (≥1 per patient) |
| Number of patient cycles |
1492 |
1319 |
|
| Number of patients with dose modification(s), n (%) |
115 (7.7%) |
63 (4.8%) |
0.016¶ |
